125 filings
Page 4 of 7
8-K
jsp90xxp188skvw1b5ii
29 Apr 22
180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology
6:44pm
8-K
rs2vs9wuy8uhi3 3l0
28 Apr 22
Departure of Directors or Certain Officers
5:07pm
8-K
hzuzbdmcasd 0xgkz4ku
14 Apr 22
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:30pm
8-K
iwtolw
28 Mar 22
Other Events
8:30am
8-K
tuma1e5dj860ix
31 Jan 22
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
8:01am
8-K
pvw gww45f6yxzk
14 Dec 21
Submission of Matters to a Vote of Security Holders
8:31am
8-K
olzgm64
10 Dec 21
Departure of Directors or Certain Officers
8:17am
8-K
il1qr9vngwhi
6 Dec 21
180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results
8:15am
8-K
rj8u7kvadxka1myqyl
1 Dec 21
Regulation FD Disclosure
2:45pm
8-K
7kp05o7g4smo168
18 Nov 21
Regulation FD Disclosure
8:16am
8-K
xvybpfy6mbo4k9btvq
2 Nov 21
Departure of Directors or Certain Officers
8:30am
8-K
80f p7d7abzp94pnau
5 Oct 21
Entry into a Material Definitive Agreement
8:16am
8-K
v80ch
20 Sep 21
Entry into a Material Definitive Agreement
4:30pm
8-K
4670bc
30 Aug 21
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders
7:30am
8-K
9i43 s5br
27 Aug 21
Unregistered Sales of Equity Securities
4:30pm
8-K
c4lqos786lleq8mcz1y7
24 Aug 21
180 Life Sciences Corp. Announces $15.0 Million Private Placement
8:30am
8-K
jkoynw m9dag
10 Aug 21
Amendments to Articles of Incorporation or Bylaws
4:31pm
8-K
ldkx0bq elwm
6 Aug 21
Unregistered Sales of Equity Securities
4:23pm
8-K
4heyrfo j1nn
2 Aug 21
Entry into a Material Definitive Agreement
4:45pm
8-K
8ryo6wvlyjcfta
20 Jul 21
Other Events
8:31am